Design and Development of a Series of Potent and Selective Type II Inhibitors of CDK8 was written by Bergeron, Philippe;Koehler, Michael F. T.;Blackwood, Elizabeth M.;Bowman, Krista;Clark, Kevin;Firestein, Ron;Kiefer, James R.;Maskos, Klaus;McCleland, Mark L.;Orren, Linda;Ramaswamy, Sreemathy;Salphati, Laurent;Schmidt, Steve;Schneider, Elisabeth V.;Wu, Jiansheng;Beresini, Maureen. And the article was included in ACS Medicinal Chemistry Letters in 2016.Safety of 4-((4-Ethylpiperazin-1-yl)methyl)-3-(trifluoromethyl)aniline This article mentions the following:
Using Sorafenib as a starting point, a series of potent and selective inhibitors of CDK8 was developed. When cocrystd. with CDK8 and cyclin C, these compounds exhibit a Type-II (DMG-out) binding mode. In the experiment, the researchers used many compounds, for example, 4-((4-Ethylpiperazin-1-yl)methyl)-3-(trifluoromethyl)aniline (cas: 630125-91-6Safety of 4-((4-Ethylpiperazin-1-yl)methyl)-3-(trifluoromethyl)aniline).
4-((4-Ethylpiperazin-1-yl)methyl)-3-(trifluoromethyl)aniline (cas: 630125-91-6) belongs to piperazine derivatives. Piperazine belongs to the family of medicines called anthelmintics. Two common salts in the form of which piperazine is usually prepared for pharmaceutical or veterinary purposes are the citrate, 3C4H10N2.2C6H8O7 (i.e. containing 3 molecules of piperazine to 2 molecules of citric acid), and the adipate, C4H10N2.C6H10O4 (containing 1 molecule each of piperazine and adipic acid).Safety of 4-((4-Ethylpiperazin-1-yl)methyl)-3-(trifluoromethyl)aniline
Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics